Our editorial team dives into the pharma industry's reaction to US tariffs on imports from the European Union and major trends from Q2 earnings calls.

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates moving forward.

Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.

Sartorius has agreed to invest $3m in Nanotein Technologies, engaged in the development of advanced immune cell activation reagents.

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.